| abstract |
An antibody that binds to IGF-IR of human IgG1 or IgG3 type and glycosylated with a sugar chain at Asn297, wherein the antibody has a quantity of fucose in the sugar chain of 99% or more and an amount of NGNA of 1% or less And / or the amount of N-terminal alpha-1, 3-galactose is 1% or less, and has improved properties in antitumor treatment. |